Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer.
BACKGROUND
To determine the immunohistochemical expression levels of the somatostatin receptor subtypes 2 and 5 (Sst2 and Sst5) in patients with colorectal cancer (CRC) and to investigate the association of Sst2 and Sst5 expression with clinicopathological parameters.


METHODS
A retrospective analysis of formalin-fixed and paraffin-embedded CRC surgical specimens from 81 patients assessed by immunohistochemistry for Sst2 and Sst5 expression.


RESULTS
Sst2 and Sst5 expression levels showed significant, negative association with CRC invasion and liver metastasis (P values < 0·05) while Sst2 also showed significantly increased expression in lower-grade tumours as well as in tumours located in the rectum (P values < 0·05). Patients with CRC expressing either Sst2 or Sst5 had significantly longer survival rates (P values < 0·05), although Sst expression was not found to be an independent predictor of survival after controlling for other known prognostic clinicopathological variables (P values > 0·05).


CONCLUSIONS
The present data confirm the relationship of Sst2 and Sst5 expression levels with reduced tumour aggressiveness.
Pathology, Nephropathology and Surgery Departments, Evangelismos Hospital, Athens, Greece.
Ioulia
I
Evangelou
Constantina
C
Petraki
Pavlos
P
Msaouel
Andreas
A
Scorilas
Eleni
E
Sdrolia
Georgia
G
Padazi
Vassilios
V
Koborozos
Michael
M
Koutsilieris
D002478:Cells, Cultured; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D017481:Receptors, Somatostatin / Q000378:metabolism*; D012189:Retrospective Studies
D017481:Receptors, Somatostatin; C094573:somatostatin receptor 5; C093733:somatostatin receptor 2